AUTHORS
Giulia Petrone, MD, Griffen R Mustion, MS2, Kyra Ddungu3, Maria Stoentcheva4, Ryan Monahan5, Geoffrey L. Uy, MD6, Eytan M Stein I, MD7, Kelly Bolton, MD, PhD8
AFFILIATIONS
1 Washington University School of Medicine, Saint Louis, Missouri, United States
2 Washington University School of Medicine, Saint Louis, Missouri, United States
3 Washington University School of Medicine, Saint Louis, Missouri, United States
4 Washington University School of Medicine, Saint Louis, United States
5 Washington University School of Medicine, Saint Louis, Missouri, United States
6 Washington University School of Medicine, Saint Louis, Missouri, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 Washington University School of Medicine, Saint Louis, Missouri, United States
ABSTRACT
Background
Clonal hematopoiesis (CH) is a process whereby hematopoietic stem cells acquire preleukemic mutations which can progress to myeloid neoplasms (MN) including myelodsyplastic syndrome (MDS) and acute myeloid leukemia (AML). CH may be present for many years before MN are diagnosed. Features associated with an increased risk of progression to MN include the presence of multiple mutations, high variant allele frequency (VAF), and mutations involving high risk genes such as IDH1/2. Individuals with CH who concurrently have unexplained cytopenias but do not fulfill the diagnostic criteria for a hematologic malignancy are diagnosed with clonal cytopenia of undetermined significance (CCUS). The estimated risk of progression to MN in patients with CCUS approaches 95% over 10 years of follow-up. Despite this exceptionally high likelihood of developing overt malignancy, there are no preventive therapies for individuals with CCUS.
Enasidenib is an IDH2 inhibitor approved for treatment of relapsed or refractory AML which has demonstrated potent inhibition of the aberrant gain-of-function activity associated with mutant IDH2. Because CCUS is associated with a lower mutational burden than AML or MDS, we hypothesize that treatment with enasidenib in patients with CCUS harboring an IDH2 mutation will produce deeper and more durable clinical responses and improve cytopenias.
Study Design and Methods
This study is a single center, open-label pilot trial designed to evaluate the therapeutic potential of enasidenib in patients with IDH2-mutant CCUS using a decentralized clinical trial (DCT) model (ClinicalTrials.gov #NCT06240754). The trial leverages telemedicine, local laboratory services and local providers, allowing eligible patients throughout the U.S. to participate remotely. This approach aims to minimize barriers to enrollment, thereby improving access for individuals with this uncommon condition, and provides a practical framework for studying rare molecular subtypes on a national scale. Eligible participants must have an IDH2 R140 or R172 mutation, and persistent unexplained cytopenia for at least 6 months. Cytopenias are defined as hemoglobin <10 g/dL, absolute neutrophil count <1.8 × 10 9/L or platelets <100 × 10 9/L, as well as adequate baseline organ function including renal and liver function. The study plans to enroll 15 participants, each receiving enasidenib 100 mg once daily for up to 18 cycles. The primary objective is to determine the rate of hematologic improvement, assessed using established MDS response criteria for erythroid, platelet, and neutrophil recovery. The trial will be considered successful if hematologic improvement is observed in at least 6 participants. Secondary objectives include serial evaluation of changes in IDH2 mutant VAF, characterizing the safety and tolerability of enasidenib, and estimating the time to AML/MDS-free survival. The study opened in one participating center in New York and by decentralized structure in October 2024, with 8 patients enrolled to date. A planned analysis will combine data from the two protocols for a total of 15 patients. If this pilot study demonstrates favorable efficacy and safety, the findings will support expansion into a larger trial aimed at determining whether early intervention with enasidenib can delay or prevent progression to overt hematologic malignancy in patients with IDH2-mutant CCUS.
DISCLOSURES
Giulia Petrone, MD: No relevant conflicts of interest to declare.